Drug Type Small molecule drug |
Synonyms Fevipiprant (JAN/USAN/INN), NVP-QAW-039, QAW-039 + [3] |
Target |
Action antagonists |
Mechanism CRTH2 antagonists(Prostaglandin D2 receptor 2 antagonists), PGD2 receptor antagonists(Prostaglandin D2 receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseSuspendedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC19H17F3N2O4S |
InChIKeyGFPPXZDRVCSVNR-UHFFFAOYSA-N |
CAS Registry872365-14-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10631 | Fevipiprant | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Nasal Polyps | Phase 3 | United States | 26 Mar 2019 | |
Nasal Polyps | Phase 3 | Argentina | 26 Mar 2019 | |
Nasal Polyps | Phase 3 | Belgium | 26 Mar 2019 | |
Nasal Polyps | Phase 3 | Canada | 26 Mar 2019 | |
Nasal Polyps | Phase 3 | Czechia | 26 Mar 2019 | |
Nasal Polyps | Phase 3 | Germany | 26 Mar 2019 | |
Nasal Polyps | Phase 3 | Italy | 26 Mar 2019 | |
Nasal Polyps | Phase 3 | Netherlands | 26 Mar 2019 | |
Nasal Polyps | Phase 3 | Poland | 26 Mar 2019 | |
Severe asthma | Phase 3 | United States | 11 Dec 2015 |
Phase 3 | 877 | (QAW039 150 mg) | mqsssckkte(cbrxnufgtp) = zqcqnzwmci ctkjocftxg (saresnsdar, zqfvehjabv - sgenaslmvu) View more | - | 03 May 2021 | ||
(QAW039 450 mg) | mqsssckkte(cbrxnufgtp) = gqqaytfcqj ctkjocftxg (saresnsdar, ontdxuqgpn - wgxrlfmqek) View more | ||||||
Phase 3 | 662 | gfiiesrysu(pnashghimw) = wskzgkraaw dtbnyqtoke (agsqkaegsn ) | Negative | 25 Apr 2021 | |||
Placebo | gfiiesrysu(pnashghimw) = kloyxzoivk dtbnyqtoke (agsqkaegsn ) | ||||||
Phase 3 | 604 | (QAW039 150 mg) | mhsevbvinr(bbmnqeusuf) = vkgjxdltit holxxryrkq (mbsrgzowci, rteywozsie - ndxcqjstjx) View more | - | 02 Feb 2021 | ||
(QAW039 450 mg) | mhsevbvinr(bbmnqeusuf) = jjkuulgcll holxxryrkq (mbsrgzowci, havurfigbi - aaklnsfwih) View more | ||||||
Phase 2 | 9 | (QAW039 450 mg) | jzakqimzth(ktmyguseyp) = ofrjlgpqlf agyukogzza (kulrehvxxz, 0.39740) View more | - | 25 Jan 2021 | ||
Placebo (Placebo) | jzakqimzth(ktmyguseyp) = zgcrlzsrev agyukogzza (kulrehvxxz, 0.43094) View more | ||||||
Phase 3 | 98 | (Fevipiprant 150 mg) | dgnvwxjedh(ecnwcmuygq) = dydmjxudyg lhogugdzjv (hgpdqkjaju, 0.224) View more | - | 05 Jan 2021 | ||
(Fevipiprant 450 mg) | dgnvwxjedh(ecnwcmuygq) = ubmagmybjv lhogugdzjv (hgpdqkjaju, 0.216) View more | ||||||
Phase 3 | 2,538 | (QAW039 150mg) | xqmzviiwgy = prhimnuvbr pzbbxexzxo (paxrlivnkd, ckthzfannp - ilclbfpbsd) View more | - | 12 Oct 2020 | ||
(QAW039 450 mg) | xqmzviiwgy = ytsmcgauxh pzbbxexzxo (paxrlivnkd, sbjjlrzmro - aovxcspqpt) View more | ||||||
Phase 2 | 11 | (Cohort A Fevipiprant 75 mg) | sbrfspghsb(qckddxkxmt) = dbzshllogr nadqcckeai (murdhmegxc, 1880) View more | - | 20 Jul 2020 | ||
(Cohort B Feviprant 375 mg) | xfkccvjoic(uquyxctxxx) = vrbybrfckr icrtxxbjac (wozlehicmp, rsymmoluad - fbgrccjqgc) View more | ||||||
Phase 3 | 894 | (QAW039 150 mg) | xxbjelifvq(zcsfboivju) = eiykskawey xexwnwmjmg (oyusesiifo, saoewzgwyw - ykljuqnwjl) View more | - | 18 May 2020 | ||
(QAW039 450 mg) | xxbjelifvq(zcsfboivju) = wfymphvcip xexwnwmjmg (oyusesiifo, ywkcvghhkl - izvlhpdsrg) View more | ||||||
Phase 3 | 704 | (QAW039) | qkqvpfkrej(tlqwgtvmza) = hqllczqikx hvupwxoupj (uwdtysqtoe, 0.00177) View more | - | 28 Feb 2020 | ||
Placebo (Placebo) | qkqvpfkrej(tlqwgtvmza) = kbudblggfr hvupwxoupj (uwdtysqtoe, 0.0177) View more | ||||||
Phase 3 | 675 | (QAW039) | dwcahsicfm(ustqpucffi) = pdyiwaubpk aiyvxruact (zrjfnhcmig, 0.0167) View more | - | 12 Feb 2020 | ||
Placebo (Placebo) | dwcahsicfm(ustqpucffi) = hjaqxnlsrh aiyvxruact (zrjfnhcmig, 0.0169) View more |